Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …

A large body of evidence generated in the last two and a half years addresses the roles of T
cells in SARS-CoV-2 infection and following vaccination. Infection or vaccination induces …

Abstract The SARS-CoV-2 Omicron variant (B. 1.1. 529) has multiple spike protein
mutations, that contribute to viral escape from antibody neutralization,,–and reduce vaccine …

Abstract The Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was initially identified in November 2021 in South Africa and Botswana, as …

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

The emergence and rapid spread of SARS-CoV-2 variants may affect vaccine efficacy
substantially. The Omicron variant termed BA. 2, which differs substantially from BA. 1 based …

Our understanding of the still unfolding severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) pandemic would have been extremely limited without the study of the …

Multiple COVID-19 vaccines, representing diverse vaccine platforms, successfully protect
against symptomatic COVID-19 cases and deaths. Head-to-head comparisons of T cell, B …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of vaccinated
individuals is increasingly common but rarely results in severe disease, likely due to the …

Spike-specific neutralizing antibodies (NAbs) are generally considered key correlates of
vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …